Nasus Pharma Ltd (NSRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | |
| Operating Expenses | 4,904 | 1,078 | 1,147 |
| Operating Income | -4,904 | -1,078 | -1,147 |
| Interest Expense | -78 | 29 | 49 |
| Other Income | -979 | -445 | 191 |
| Pre-tax Income | -5,805 | -1,552 | -1,005 |
| Net Income Continuous | -5,805 | -1,552 | -1,005 |
| Net Income Discontinuous | -51 | 20 | -46 |
| Net Income | $-5,856 | $-1,532 | $-1,051 |
| EPS Basic Total Ops | -0.72 | -0.22 | -0.15 |
| EPS Basic Continuous Ops | -0.72 | -0.22 | -0.15 |
| EPS Basic Discontinuous Ops | -0.01 | 0.00 | -0.01 |
| EPS Diluted Total Ops | -0.72 | -0.22 | -0.20 |
| EPS Diluted Continuous Ops | -0.72 | -0.22 | -0.14 |
| EPS Diluted Discontinuous Ops | -0.01 | 0.00 | -0.01 |
| EPS Diluted Before Non-Recurring Items | -0.72 | -0.22 | N/A |
| EBITDA(a) | $-4,904 | $-1,078 | $-1,147 |